Neutrophil-to-lymphocyte ratio combined with albumin to globulin ratio for predicting rheumatoid arthritis-associated pneumonia

中性粒细胞与淋巴细胞比值联合白蛋白与球蛋白比值预测类风湿性关节炎相关性肺炎

阅读:1

Abstract

OBJECTIVE: Rheumatoid arthritis-associated pneumonia (RAP) is a common complication of rheumatoid arthritis (RA) and is related to poor prognosis. Inflammation plays an important role in the development of RAP. This study aims to analyze and explore the predictive value of the neutrophil/lymphocyte ratio (NLR) combined with the albumin to globulin ratio (AGR) for assessing RAP. METHODS: Data for this study were collected retrospectively from the database of Xuancheng People's Hospital between February 2021 and November 2023. Patients with RAP were assigned to the observation group (n=78), while patients with rheumatoid arthritis (RA) alone were assigned to the control group (n=75). The differences in general clinical data, NLR, and AGR were compared between the two groups. Risk factors for RAP were analyzed using univariate and multivariate Logistic regression. RESULTS: The observation group had significantly lower AGR levels and higher NLR levels compared to the control group (all P<0.05). Univariate and multivariate logistic regression analyses identified age (95% CI 1.265-3.468; P=0.007), glucocorticoid use (95% CI 1.187-3.187; P=0.009), usage of disease-modifying anti-rheumatic drugs (DMARDs) (95% CI 1.257-2.997; P=0.006), AGR (95% CI 1.147-3.578; P=0.012), NLR (95% CI 1.198-2.978; P=0.008) and course of disease (95% CI 11.178-2.971; P=0.005) as independent prognostic factors for RAP. In addition, the ROC curve analysis showed that joint detection of NLR and AGR had a sensitivity of 98.8% and specificity of 81.8% for predicting RAP. CONCLUSION: NLR and AGR play significant roles in the occurrence and progression of RAP and can serve as predictive factors for early detection of RAP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。